Alicia Jenkins to Double-Blind Method
This is a "connection" page, showing publications Alicia Jenkins has written about Double-Blind Method.
Connection Strength
0.206
-
Metformin and carotid intima-media thickness in never-smokers with type 1 diabetes: The REMOVAL trial. Diabetes Obes Metab. 2021 06; 23(6):1371-1378.
Score: 0.034
-
FKBPL is associated with metabolic parameters and is a novel determinant of cardiovascular disease. Sci Rep. 2020 12 10; 10(1):21655.
Score: 0.033
-
Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017 08; 5(8):597-609.
Score: 0.026
-
Metformin in adults with type 1 diabetes: Design and methods of REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL): An international multicentre trial. Diabetes Obes Metab. 2017 04; 19(4):509-516.
Score: 0.026
-
Opposite associations between alanine aminotransferase and ?-glutamyl transferase levels and all-cause mortality in type 2 diabetes: Analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Metabolism. 2016 May; 65(5):783-793.
Score: 0.024
-
Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study. Diabetologia. 2015 Sep; 58(9):2035-44.
Score: 0.023
-
Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia. 2014 Nov; 57(11):2296-303.
Score: 0.022
-
Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2012 Dec; 97(12):4701-8.
Score: 0.019